Understanding GLP-1 medicines

A short guide to the terminology

Active ingredient names the medicine's pharmacological substance, such as semaglutide, tirzepatide or orforglipron. Brand is the product name. Formulation describes how it is made and delivered, such as a tablet or injection. Presentation can identify the particular strength, pack or device.

These distinctions prevent a common error: assuming that instructions can be copied from any product in the same family. The UK product information for Ozempic, Wegovy tablets and Foundayo illustrates three different products, even though all are discussed under the broad GLP-1 heading. [2][3][4]

When asking for help, give the full name on the carton, its strength and whether it is a tablet or a particular pen. A photograph of the label can help your pharmacist, but avoid sharing identifying prescription details in public forums.

Where the main names fit

Mounjaro contains tirzepatide and activates GIP as well as GLP-1 receptors. Ozempic and Wegovy contain semaglutide, but their authorised uses and presentations differ. Foundayo contains orforglipron, a different oral GLP-1 receptor agonist. [5][2][4]

Wegovy tablets received UK authorisation in June 2026, and Foundayo in August 2026. Current information must therefore distinguish daily oral treatment from weekly injections. Describing every GLP-1 product as a “weight-loss jab” is no longer an accurate introduction. [6][4]

Some products are used for type 2 diabetes, some for weight management, and some have additional indications in defined groups. Ask which indication is relevant to your prescription rather than treating the brand as a general treatment for every metabolic condition.

What licensed, recommended and available mean

A marketing authorisation defines the uses, doses and precautions under which a medicine was assessed. Off-label use means using a licensed medicine outside those terms; it is a prescribing decision with responsibilities for explanation and monitoring. [7]

NICE recommendations and NHS implementation add a separate layer. They address clinical and cost effectiveness and how treatment is provided. England's phased tirzepatide arrangements are one example of access being narrower or more gradual than the product licence alone might suggest. [8]

For a practical enquiry, ask three separate questions: is the treatment authorised for this purpose, does the relevant NHS service offer it under its current criteria, and can the pharmacy supply the exact presentation? Keeping those questions separate helps avoid both false reassurance and unnecessary confusion.

How to read a treatment claim

A randomised trial compares groups assigned to treatments. A placebo comparison answers a different question from a direct comparison between two active medicines. Average weight change is different from the proportion of people reaching a specified threshold. A change in a risk score is different from observing fewer heart attacks.

For example, SURMOUNT-5 compared particular injected tirzepatide and semaglutide regimens, not every product sharing those names. OASIS 4 compared oral semaglutide 25 mg with placebo. The route and comparator belong in a fair summary. [9][10]

Check the follow-up time and whether the analysis includes people who stopped treatment. A trial result should help frame expectations without becoming a promised outcome, a compulsory target or a reason to increase a dose independently.

What a useful assessment includes

NICE's practical prescribing guide describes assessment, monitoring and review as part of medicine-based weight management. NHS England also distinguishes clinical support from broader dietary, activity and behavioural care. [11][12]

Prepare a current medicine list, relevant medical history and the questions most important to you. Include previous treatment experiences, planned surgery, pregnancy intentions, practical barriers and the outcome you hope to improve. Ask which of those matters affects the choice and who will coordinate care if several services are involved.

Before starting, request a clear explanation of the prescribed routine, next review and contact route for problems. Ask what would lead to continuing, changing or stopping treatment. The review plan should be understandable without needing to interpret a trial paper yourself.

Safety belongs to the exact product

Read the supplied leaflet before first use and again if the presentation changes. For example, Wegovy FlexTouch contains multiple injections while the separate 7.2 mg pen is single use. A common brand name does not make the devices interchangeable. [13][14]

Severe, persistent abdominal pain needs urgent assessment because it may indicate pancreatitis. The MHRA has strengthened warnings for GLP-1 and dual GIP/GLP-1 medicines. [15]

Tell the prescriber about pregnancy intentions and contraception. Ask them to check the exact product's advice; the intervals and precautions differ between medicines.

Obtain treatment through a legitimate prescription and registered pharmacy. If buying care online, check registration, how the assessment works and who provides aftercare. [16]

Questions and answers